Head-to-head · WeighScore
Piper vs Precision Telemed
The verdict
Precision Telemed takes it — 83.8/100 to 81.9/100, but only just.
Precision Telemed grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Round mid-market pricing ($149/$199), verified and available nationwide. Piper is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Piper | Precision Telemed |
|---|---|---|
| WeighScore | 81.9/100 | 83.8/100 |
| Grade | B− | B |
| Scorecard rank | #30 | #22 |
| Semaglutide | $135/mo | $149/mo |
| Tirzepatide | $199/mo | $199/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #30 · B−
Strengths
- $135 sema / $199 tirz
- All 50 states
- Both molecules
Where it loses points
- Not LegitScript-verified
- Injection-only
- Monitoring detail limited
Graded #22 · B
Strengths
- $149 sema / $199 tirz
- All 50 states, LegitScript-verified
- Both molecules
Where it loses points
- Mid-pack pricing
- Injection-only
- Monitoring detail limited
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 509 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.